FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1065-1072 October 7, 1993 Number 15 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The non-nucleoside reverse transcriptase inhibitors are novel antiretroviral agents with selective activity in vitro against human immunodeficiency virus type 1 (HIV-1). They act through direct inhibition of reverse transcriptase and are not incorporated into DNA.

Methods We evaluated a pyridinone non-nucleoside reverse transcriptase inhibitor, L-697,661, in separate six-week double-blind trials in patients with HIV-1 infection whose CD4 counts ranged from 200 to 500 cells per cubic millimeter (68 patients) or less than 200 cells per cubic millimeter (67 patients). Eligible patients were randomly assigned to receive L-697,661 orally in one of three doses (25 mg twice a day, 100 mg three times a day, or 500 mg twice a day) or zidovudine (100 mg five times a day). Clinical and laboratory assessments were performed weekly. Viral isolates were obtained from a subgroup of patients before and after treatment and were evaluated for in vitro sensitivity to L-697,661.

Results Both L-697,661 and zidovudine were well tolerated. Transient increases in CD4 counts were noted in the patients with fewer than 200 CD4 cells per cubic millimeter who received the two higher doses of L-697,661, but not in those who received the lowest dose or zidovudine. Patients who received L-697,661 had rapid, dose-related decreases in plasma p24 antigen levels. However, this response virtually disappeared after six weeks in some patients receiving L-697,661, coincidently with the emergence of resistant viruses. This change in susceptibility was more frequent among patients receiving the higher doses of L-697,661 and was associated with amino acid substitutions at positions 103 and 181 in the HIV-1 reverse transcriptase gene.

Conclusions L-697,661 is safe and well tolerated and has significant dose-related activity against HIV-1. However, resistant strains of the virus emerge rapidly and may limit the effectiveness of non-nucleoside reverse transcriptase inhibitors as monotherapy for HIV-1 infection.

Source Information

From the Department of Medicine, University of Alabama at Birmingham (M.S.S., J.D., W.I.L., R.J.W., J.C.K., G.M.S.), and Merck Research Laboratories, West Point, Pa. (E.A.E., O.L.L., W.A.S., C.H., V.W.B., K.W.A., F.E.M.). The members of the L-697,661 Working Group are listed in the Appendix.

Address reprint requests to Dr. Saag at the University of Alabama at Birmingham, 908 S. 20th St., #245B, Birmingham, AL 35294-2050.

Full Text of this Article

This article has been cited by other articles:

• Hazuda, D. J., Anthony, N. J., Gomez, R. P., Jolly, S. M., Wai, J. S., Zhuang, L., Fisher, T. E., Embrey, M., Guare, J. P. Jr., Egbertson, M. S., Vacca, J. P., Huff, J. R., Felock, P. J., Witmer, M. V., Stillmock, K. A., Danovich, R., Grobler, J., Miller, M. D., Espeseth, A. S., Jin, L., Chen, I-W., Lin, J. H., Kassahun, K., Ellis, J. D., Wong, B. K., Xu, W., Pearson, P. G., Schleif, W. A., Cortese, R., Emini, E., Summa, V., Holloway, M. K., Young, S. D. (2004). From the Cover: A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 101: 11233-11238 [Abstract] [Full Text]  
• Huang, W., Gamarnik, A., Limoli, K., Petropoulos, C. J., Whitcomb, J. M. (2002). Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus Replication. J. Virol. 77: 1512-1523 [Abstract] [Full Text]  
• Grant, R. M., Hecht, F. M., Warmerdam, M., Liu, L., Liegler, T., Petropoulos, C. J., Hellmann, N. S., Chesney, M., Busch, M. P., Kahn, J. O. (2002). Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons. JAMA 288: 181-188 [Abstract] [Full Text]  
• Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., Kappes, J. C. (2002). Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy. Antimicrob. Agents Chemother. 46: 1896-1905 [Abstract] [Full Text]  
• Buckheit, R. W. Jr., Watson, K., Fliakas-Boltz, V., Russell, J., Loftus, T. L., Osterling, M. C., Turpin, J. A., Pallansch, L. A., White, E. L., Lee, J.-W., Lee, S.-H., Oh, J.-W., Kwon, H.-S., Chung, S.-G., Cho, E.-H. (2001). SJ-3366, a Unique and Highly Potent Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) That Also Inhibits HIV-2. Antimicrob. Agents Chemother. 45: 393-400 [Abstract] [Full Text]  
• Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden-Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., Reichman, R. C. (2000). Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260). Antimicrob. Agents Chemother. 44: 794-797 [Abstract] [Full Text]  
• Buckheit, R. W. Jr., White, E. L., Fliakas-Boltz, V., Russell, J., Stup, T. L., Kinjerski, T. L., Osterling, M. C., Weigand, A., Bader, J. P. (1999). Unique Anti-Human Immunodeficiency Virus Activities of the Nonnucleoside Reverse Transcriptase Inhibitors Calanolide A, Costatolide, and Dihydrocostatolide. Antimicrob. Agents Chemother. 43: 1827-1834 [Abstract] [Full Text]  
• Para, M. F., Meehan, P., Holden-Wiltse, J., Fischl, M., Morse, G., Shafer, R., Demeter, L. M., Wood, K., Nevin, T., Virani-Ketter, N., Freimuth, W. W. (1999). ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy. Antimicrob. Agents Chemother. 43: 1373-1378 [Abstract] [Full Text]  
• Patick, A. K., Potts, K. E. (1998). Protease Inhibitors as Antiviral Agents. Clin. Microbiol. Rev. 11: 614-627 [Abstract] [Full Text]  
• Goldschmidt, P. L., Devillechabrolle, A., Ait-Arkoub, Z., Aubin, J.-T. (1998). Comparison of an Amplified Enzyme-Linked Immunosorbent Assay with Procedures Based on Molecular Biology for Assessing Human Immunodeficiency Virus Type 1 Viral Load. CVI 5: 513-518 [Abstract] [Full Text]  
• Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vezinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Vella, S., Richman, D. D., for the International AIDS Society-USA Panel, (1998). Antiretroviral Drug Resistance Testing in Adults With HIV Infection: Implications for Clinical Management. JAMA 279: 1984-1991 [Abstract] [Full Text]  
• Eastman, P. S., Mittler, J., Kelso, R., Gee, C., Boyer, E., Kolberg, J., Urdea, M., Leonard, J. M., Norbeck, D. W., Mo, H., Markowitz, M. (1998). Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy. J. Virol. 72: 5154-5164 [Abstract] [Full Text]  
• Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., Thompson, M. A., Vella, S., Yeni, P. G., Volberding, P. A. (1996). Antiretroviral Therapy for HIV Infection in 1996: Recommendations of an International Panel. JAMA 276: 146-154 [Abstract]  
• O'Brien, W. A., Hartigan, P. M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M. S., Hamilton, J. D. (1996). Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS. NEJM 334: 426-431 [Abstract] [Full Text]